COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04951622




Registration number
NCT04951622
Ethics application status
Date submitted
30/06/2021
Date registered
7/07/2021
Date last updated
15/10/2021

Titles & IDs
Public title
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Scientific title
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Secondary ID [1] 0 0
2020-005732-29
Secondary ID [2] 0 0
CR109046
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Myasthenia Gravis 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Neurological 0 0 0 0
Other neurological disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Nipocalimab
Treatment: Drugs - Placebo

Experimental: Nipocalimab - Double-blind Placebo-controlled Phase: Participants will receive nipocalimab intravenous (IV) infusions once every 2 weeks (q2w) up to 24 weeks during double-blind placebo-controlled phase.
Open-label Extension (OLE) Phase: Participants who complete the double-blind placebo-controlled phase will enter the OLE phase and continue to receive nipocalimab q2w IV infusion from OLE Day 1 to 24 weeks. Participants who are stable on the q2w dosing regimen can be transitioned to a dosing regimen every 4 weeks (q4w) during OLE phase.

Placebo Comparator: Placebo - Double-blind Placebo-controlled Phase: Participants will receive matching placebo of nipocalimab IV infusion q2w up to 24 weeks during double-blind placebo-controlled phase.


Treatment: Drugs: Nipocalimab
Nipocalimab will be administered as an IV infusion.

Treatment: Drugs: Placebo
Matching placebo will be administered as an IV infusion.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Average Change from Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Score - Average change from baseline in MG-ADL score over Weeks 22, 23 and 24 of the double-blind placebo-controlled phase will be reported. Averaging over multiple time points (Weeks 22, 23 and 24) will be done to get a single measure. The MG-ADL provides a rapid assessment of the participant's MG symptom severity. Eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, eyelid droop) are rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score will be sum of eight function scores and can range from 0 to 24. A higher score indicates greater symptom severity.
Timepoint [1] 0 0
Baseline up to Week 24
Secondary outcome [1] 0 0
Average Change in Quantitative Myasthenia Gravis (QMG) Score Over Weeks 22 and 24 of the Double-blind Placebo-controlled Phase - Average change in QMG score over Weeks 22 and 24 of the double-blind placebo-controlled phase will be reported. The QMG test is a standardized quantitative strength assessment comprising 13 components. The quantitative results of each strength component are mapped to the following 4-point scale: 0 equals to (=) none, 1 = mild, 2 = moderate and 3 = severe. The total score will be sum of 13 components scores and can range from 0 to 39. A higher score indicates greater weakness.
Timepoint [1] 0 0
Up to Weeks 22 and 24
Secondary outcome [2] 0 0
Percentage of Participants whose Average MG-ADL Total Score Over Weeks 22, 23, and 24 is at least a 2-Point Improvement from Baseline of the Double-blind Placebo-controlled Phase - Percentage of participants whose average MG-ADL total score over Weeks 22, 23, and 24 is at least a 2-point improvement from baseline of the double-blind placebo-controlled phase will be reported.
Timepoint [2] 0 0
Baseline up to Weeks 22, 23 and 24
Secondary outcome [3] 0 0
Percentage of Participants with Improvement in MG-ADL Total Score Greater Than Or Equal to (>=) 2 Points at Week 1 and/or Week 2 of the Double-blind Placebo-controlled Phase - Percentage of participants with improvement in MG-ADL total score >= 2 points at Week 1 and/or Week 2 of the double-blind placebo-controlled phase will be reported.
Timepoint [3] 0 0
Weeks 1 and 2
Secondary outcome [4] 0 0
Average Percentage of Participants with MG-ADL Score of 0 or 1 Over Weeks 22, 23 and 24 of the Double-blind Placebo-controlled Phase - The average percentage of participants with MG-ADL score of 0 or 1 over Weeks 22, 23 and 24 of the double-blind placebo-controlled phase will be reported.
Timepoint [4] 0 0
Up to Weeks 22, 23 and 24
Secondary outcome [5] 0 0
Percentage of Participants with Improvement in MG-ADL Total Score >= 2 Points at Week 2 through Week 24 of the Double-blind Placebo-controlled Phase with No More Than 2 Excursions Allowed at Weeks 3 through 23 - Percentage of participants with improvement in MG-ADL total score >= 2 points at Week 2 through Week 24 of the double-blind placebo-controlled phase with no more than 2 excursions allowed at Weeks 3 through 23 (excursion is defined as loss of improvement in MG-ADL score >= 2 points) will be reported.
Timepoint [5] 0 0
Week 2 up to Week 24
Secondary outcome [6] 0 0
Percentage of Participants with Adverse Events (AEs) - An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Timepoint [6] 0 0
Up to Week 24 of double-blind placebo-controlled phase and up to extension Week 24 of open-label extension phase (up to Week 48)
Secondary outcome [7] 0 0
Percentage of Participants with Serious Adverse Events (SAEs) - A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.
Timepoint [7] 0 0
Up to Week 24 of double-blind placebo-controlled phase and up to extension Week 24 of open-label extension phase (up to Week 48)
Secondary outcome [8] 0 0
Percentage of Participants with Adverse Events of Special Interest (AESIs) - Percentage of participants with AESIs will be reported. Treatment-emergent AEs associated with the following situations are considered as AESI: 1) severe or medically significant or immediately life-threatening infections requiring intravenous (IV) anti-infective or operative/invasive intervention or requiring hospitalization or prolongation of existing hospitalization; 2) hypoalbuminemia with albumin less than (<) 20 grams per liter (g/L). Treatment-emergent AEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.
Timepoint [8] 0 0
Up to Week 24 of double-blind placebo-controlled phase and up to extension Week 24 of open-label extension phase (up to Week 48)
Secondary outcome [9] 0 0
Percentage of Participants with Change in Vital Signs - Percentage of participants with change in vital signs (temperature, blood pressure and heart rate) will be reported.
Timepoint [9] 0 0
Up to Week 24 of double-blind placebo-controlled phase and up to extension Week 24 of open-label extension phase (up to Week 48)
Secondary outcome [10] 0 0
Percentage of Participants with Change in Clinical Laboratory Values - Percentage of participants with change in clinical laboratory (serum chemistry, hematology, lipid profiles and urinalysis) values will be reported.
Timepoint [10] 0 0
Up to Week 24 of double-blind placebo-controlled phase and up to extension Week 24 of open-label extension phase (up to Week 48)
Secondary outcome [11] 0 0
Percentage of Participants with Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Score - Percentage of participants with change in C-SSRS scale score will be reported. C-SSRS is semi structured clinician-administered questionnaire designed to solicit the occurrence, severity, and frequency of suicide-related ideation and behaviors. Total score ranges from 1 to 10. Higher scores indicate greater severity.
Timepoint [11] 0 0
Up to Week 24 of double-blind placebo-controlled phase and up to extension Week 24 of open-label extension phase (up to Week 48)
Secondary outcome [12] 0 0
Percentage of Participants with Improvement in QMG Score of >= 3 Points from Baseline at Week 2 through Week 24 of the Double-blind Placebo-controlled Phase with No More than 2 Excursions Allowed at Weeks 4 through 22 - Percentage of participants with improvement in QMG score of >= 3 points from baseline at Week 2 through Week 24 of the double-blind placebo-controlled phase with no more than 2 excursions allowed at weeks 4 through 22 (excursions defined as loss of improvement in QMG score of >= 3 points) will be reported.
Timepoint [12] 0 0
Week 2 up to Week 24
Secondary outcome [13] 0 0
Average Change From Baseline in the Fatigue Items of the Quality of Life in Neurological Disorders Scale (Neuro-QoL Fatigue) Total Score Over Weeks 22 and 24 of Double-blind Placebo-controlled Phase - Average change from baseline in the Neuro-QoL Fatigue total score over Weeks 22 and 24 of double-blind placebo-controlled phase will be reported. Neuro-QoL fatigue is a 19-item questionnaire developed and validated for use in common neurological conditions which assesses patient-reported fatigue and associated impact on physical, mental, and social activities during the past 7 days. Each item included in the Neuro-QoL Fatigue questionnaire is graded on a 5-point Likert-type scale (1=Never; 2=Rarely; 3=Sometimes; 4=Often; 5=Always). The total scores are calculated by summing 19 items score and can range from 19-95. Higher score reflects more fatigue.
Timepoint [13] 0 0
Baseline up to Weeks 22 and 24
Secondary outcome [14] 0 0
Average Change from Baseline in the Revised Myasthenia Gravis Quality of Life - 15 Scale (MG-Qol15r) Score Over Weeks 22 And 24 of the Double-blind Placebo-controlled Phase - Average change from baseline in the MG-QoL15r score over Weeks 22 and 24 of the double-blind placebo-controlled phase will be reported. The MG-QoL15r is a participant-reported outcome instrument that measures MG-specific health-related quality of life. The MG-QoL15r contains 15 items that evaluate patients' experience related to Myasthenia Gravis over the "past few weeks" on a 3-point Likert-type scale (0=Not at all; 1=Somewhat; 2=Very much). The total score of the MG-QoL15r can be calculated by summing 15 items score and can range from 0 to 30. A higher score indicates poorer health related quality of life.
Timepoint [14] 0 0
Baseline up to Weeks 22 and 24
Secondary outcome [15] 0 0
Change from Baseline in the Visual Analog Scale (VAS) Score of European Quality of Life (EuroQol) 5-Dimension 5-Level (EQ-5D-5L) Scale Over 24 Weeks of the Double-blind Placebo-controlled Phase - Change from baseline in the VAS score of EQ-5D-5L scale over 24 weeks of the double-blind placebo-controlled phase will be reported. EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state). Positive change in score indicates improvement.
Timepoint [15] 0 0
Baseline up to 24 weeks
Secondary outcome [16] 0 0
Change from Baseline in the Health Status Index of the EQ-5D-5L Scale Over 24 Weeks of the Double-blind Placebo-controlled Phase - Change from baseline in health status index of EQ-5D-5L scale over 24 weeks of double-blind placebo-controlled phase will be reported. EQ-5D-5L is standardized instrument for use as measure of health outcome, primarily designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ-VAS. EQ-5D-5L descriptive system comprises following 5 dimensions: Mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of 5 dimensions is divided into 5 levels of perceived problems (1 indicating no problem, 2 indicating slight problems, 3 indicating moderate problems, 4 indicating severe problems, 5 indicating extreme problems). Participant selects an answer for each of 5 dimensions considering response that best matches his or her health "today". The responses to 5 dimensions are used to compute a single score ranging from zero (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of the individual.
Timepoint [16] 0 0
Baseline up to 24 weeks
Secondary outcome [17] 0 0
Serum Nipocalimab Concentrations Over Time - Serum nipocalimab concentrations over time will be reported.
Timepoint [17] 0 0
Up to 4 years and 8 months
Secondary outcome [18] 0 0
Number of Participants with Antibodies to Nipocalimab (Anti-Drug Antibodies [ADAs] and Neutralizing Antibodies [NAbs]) - Number of participants with antibodies to nipocalimab (ADAs and NAbs) will be reported.
Timepoint [18] 0 0
Up to 4 years and 8 months
Secondary outcome [19] 0 0
Change in Total Serum Immunoglobulin G (IgG) Concentrations - Change in total serum IgG concentrations will be reported.
Timepoint [19] 0 0
Up to 4 years and 8 months
Secondary outcome [20] 0 0
Change in Levels of Autoantibodies Associated with Generalized Myasthenia Gravis (gMG) - Change in levels of autoantibodies associated with gMG will be reported.
Timepoint [20] 0 0
Up to 4 years and 8 months
Secondary outcome [21] 0 0
Change from Baseline in MG-ADL Score as a Function of IgG - Change from baseline in MG-ADL score as a function of IgG will be reported.
Timepoint [21] 0 0
Baseline up to 4 years and 8 months
Secondary outcome [22] 0 0
Change from Baseline in QMG Score as a Function of IgG - Change from baseline in QMG score as a function of IgG will be reported.
Timepoint [22] 0 0
Baseline up to 4 years and 8 months
Secondary outcome [23] 0 0
Change From Baseline in MG-ADL Score as a Response to Percent Change in Autoantibody Levels, in Seropositive Participants Treated with Nipocalimab - Change from baseline in MG-ADL score as a response to percent change in autoantibody levels, in seropositive participants (anti-acetylcholine receptor [anti-AChR], anti-muscle-specific kinase [anti-MuSK], anti-lipoprotein-related protein receptor 4 [anti-LRP4]) treated with nipocalimab will be reported.
Timepoint [23] 0 0
Baseline up to 4 years and 8 months
Secondary outcome [24] 0 0
Potential Relationship Between Change in QMG Score - Potential relationship between change in QMG score will be evaluated.
Timepoint [24] 0 0
Up to 4 years and 8 months

Eligibility
Key inclusion criteria
- Diagnosis of myasthenia gravis (MG) with generalized muscle weakness meeting the
clinical criteria for generalized myasthenia gravis (gMG) as defined by the Myasthenia
Gravis Foundation of America (MGFA) Clinical Classification Class II a/b, III a/b, or
IVa/b at screening

- Myasthenia Gravis - Activities of Daily Living (MG-ADL) score of greater than or equal
to (>=) 6 at screening and baseline

- Has sufficient venous access to allow drug administration by infusion and blood
sampling as per the protocol

- A woman of childbearing potential must have a negative highly sensitive serum
(beta-human chorionic gonadotropin [beta-hCG]) at screening and a negative urine
pregnancy test at Day 1 prior to administration of study intervention

- A male participant must agree not to donate sperm for the purpose of reproduction
during the study and for a minimum 90 days after receiving the last administration of
study intervention
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Has any confirmed or suspected clinical immunodeficiency syndrome not related to
treatment of his/her gMG, or has a family history of congenital or hereditary
immunodeficiency unless confirmed absent in the participant

- Has MGFA Class I disease or presence of MG crisis (MGFA Class V) at screening, history
of MG crisis within 1 month of screening, or fixed weakness (and/or 'burnt out' MG)

- Has had a thymectomy within 12 months prior to screening, or thymectomy is planned
during the study

- Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients

- Has experienced myocardial infarction, unstable ischemic heart disease, or stroke
within 12 weeks of screening

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Melbourne Neurology Group - North Melbourne
Recruitment hospital [2] 0 0
Gold Coast University Hospital - Southport
Recruitment postcode(s) [1] 0 0
3051 - North Melbourne
Recruitment postcode(s) [2] 0 0
4215 - Southport
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nevada
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Vermont
Country [19] 0 0
Belgium
State/province [19] 0 0
Anderlecht
Country [20] 0 0
Belgium
State/province [20] 0 0
Brugge
Country [21] 0 0
Belgium
State/province [21] 0 0
Brussels
Country [22] 0 0
Belgium
State/province [22] 0 0
Gent
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Canada
State/province [24] 0 0
British Columbia
Country [25] 0 0
Canada
State/province [25] 0 0
Ontario
Country [26] 0 0
Canada
State/province [26] 0 0
Quebec
Country [27] 0 0
China
State/province [27] 0 0
Beijing
Country [28] 0 0
China
State/province [28] 0 0
BeiJing
Country [29] 0 0
China
State/province [29] 0 0
Changchun
Country [30] 0 0
China
State/province [30] 0 0
Changsha
Country [31] 0 0
China
State/province [31] 0 0
Chengdu
Country [32] 0 0
China
State/province [32] 0 0
Fuzhou
Country [33] 0 0
China
State/province [33] 0 0
Guangzhou
Country [34] 0 0
China
State/province [34] 0 0
Hangzhou
Country [35] 0 0
China
State/province [35] 0 0
Jinan
Country [36] 0 0
China
State/province [36] 0 0
Shanghai
Country [37] 0 0
China
State/province [37] 0 0
Tianjin
Country [38] 0 0
China
State/province [38] 0 0
Xi'An
Country [39] 0 0
Colombia
State/province [39] 0 0
Bucaramanga
Country [40] 0 0
Colombia
State/province [40] 0 0
Floridablanca
Country [41] 0 0
Czechia
State/province [41] 0 0
Brno
Country [42] 0 0
Czechia
State/province [42] 0 0
Ostrava
Country [43] 0 0
Czechia
State/province [43] 0 0
Praha
Country [44] 0 0
Denmark
State/province [44] 0 0
Aalborg
Country [45] 0 0
Denmark
State/province [45] 0 0
Aarhus
Country [46] 0 0
Denmark
State/province [46] 0 0
København Ø
Country [47] 0 0
France
State/province [47] 0 0
Bron
Country [48] 0 0
France
State/province [48] 0 0
Grenoble
Country [49] 0 0
France
State/province [49] 0 0
Paris
Country [50] 0 0
France
State/province [50] 0 0
Provence-Alpes-Côte d'Azur
Country [51] 0 0
Germany
State/province [51] 0 0
Berlin
Country [52] 0 0
Germany
State/province [52] 0 0
Gummersbach
Country [53] 0 0
Germany
State/province [53] 0 0
Göttingen
Country [54] 0 0
Germany
State/province [54] 0 0
Jena
Country [55] 0 0
Germany
State/province [55] 0 0
Leipzig
Country [56] 0 0
Germany
State/province [56] 0 0
München
Country [57] 0 0
Germany
State/province [57] 0 0
Ulm
Country [58] 0 0
Germany
State/province [58] 0 0
Wiesbaden
Country [59] 0 0
Italy
State/province [59] 0 0
Catania
Country [60] 0 0
Italy
State/province [60] 0 0
Milano
Country [61] 0 0
Italy
State/province [61] 0 0
Napoli
Country [62] 0 0
Italy
State/province [62] 0 0
Pavia
Country [63] 0 0
Italy
State/province [63] 0 0
Roma
Country [64] 0 0
Japan
State/province [64] 0 0
Chiba
Country [65] 0 0
Japan
State/province [65] 0 0
Hanamaki
Country [66] 0 0
Japan
State/province [66] 0 0
Hiroshima-shi
Country [67] 0 0
Japan
State/province [67] 0 0
Kita-Gun
Country [68] 0 0
Japan
State/province [68] 0 0
Kumamoto
Country [69] 0 0
Japan
State/province [69] 0 0
Morioka-shi
Country [70] 0 0
Japan
State/province [70] 0 0
Nagoya-shi
Country [71] 0 0
Japan
State/province [71] 0 0
Niigata
Country [72] 0 0
Japan
State/province [72] 0 0
Nishinomiya-Shi
Country [73] 0 0
Japan
State/province [73] 0 0
Osaka-Sayama-shi
Country [74] 0 0
Japan
State/province [74] 0 0
Sapporo
Country [75] 0 0
Japan
State/province [75] 0 0
Sendai
Country [76] 0 0
Japan
State/province [76] 0 0
Tokushima
Country [77] 0 0
Japan
State/province [77] 0 0
Tokyo
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Busan
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Daegu
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Seodaemun
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Seoul
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Yangsan-si
Country [83] 0 0
Mexico
State/province [83] 0 0
Aguascalientes
Country [84] 0 0
Mexico
State/province [84] 0 0
Cuernavaca
Country [85] 0 0
Mexico
State/province [85] 0 0
Guadalajara
Country [86] 0 0
Poland
State/province [86] 0 0
Bydgoszcz
Country [87] 0 0
Poland
State/province [87] 0 0
Katowice
Country [88] 0 0
Poland
State/province [88] 0 0
Krakow
Country [89] 0 0
Poland
State/province [89] 0 0
Lodz
Country [90] 0 0
Poland
State/province [90] 0 0
Lublin
Country [91] 0 0
Poland
State/province [91] 0 0
Warsaw
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Barnaul
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Kazan
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Kemerovo
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Moscow
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Nizhniy Novgorod
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Novosibirsk
Country [98] 0 0
Russian Federation
State/province [98] 0 0
St. Petersburg
Country [99] 0 0
Spain
State/province [99] 0 0
Alicante
Country [100] 0 0
Spain
State/province [100] 0 0
Barcelona
Country [101] 0 0
Spain
State/province [101] 0 0
Bilbao
Country [102] 0 0
Spain
State/province [102] 0 0
Madrid
Country [103] 0 0
Spain
State/province [103] 0 0
Sevilla
Country [104] 0 0
Spain
State/province [104] 0 0
Valencia
Country [105] 0 0
Sweden
State/province [105] 0 0
Karlstad
Country [106] 0 0
Sweden
State/province [106] 0 0
Stockholm
Country [107] 0 0
Taiwan
State/province [107] 0 0
Kaohsiung
Country [108] 0 0
Taiwan
State/province [108] 0 0
Taichung
Country [109] 0 0
Taiwan
State/province [109] 0 0
Taipei
Country [110] 0 0
Turkey
State/province [110] 0 0
Fatih
Country [111] 0 0
Turkey
State/province [111] 0 0
Istanbul
Country [112] 0 0
Turkey
State/province [112] 0 0
Konya
Country [113] 0 0
Turkey
State/province [113] 0 0
Mersin
Country [114] 0 0
Turkey
State/province [114] 0 0
Trabzon
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Birmingham
Country [116] 0 0
United Kingdom
State/province [116] 0 0
London
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to
placebo in participants with generalized myasthenia gravis (gMG).
Trial website
https://clinicaltrials.gov/show/NCT04951622
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Contact
Address 0 0
Country 0 0
Phone 0 0
844-434-4210
Fax 0 0
Email 0 0
JNJ.CT@sylogent.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT04951622